Thyroid hormone, brain development, and the environment. by Zoeller, Thomas R et al.
The importance of thyroid hormone in
brain development has been extensively doc-
umented and reviewed for animals (1–13)
and humans (14–22). These reviews leave no
doubt that thyroid hormone deﬁcit or excess
during development can have permanent,
pervasive, and profound effects on adult
neurological function. Recent studies also
demonstrate that relatively subtle changes in
circulating levels of thyroid hormone in
pregnant women can affect the neurological
outcome of their children (23–27). Thus, it
is clear that the fetus and neonate are quite
sensitive to thyroid hormone. However,
despite the known importance of thyroid
hormone for normal brain development, and
new insight into the sensitivity of neural
development to maternal thyroid status,
there are critical gaps in our understanding
of thyroid hormone and brain development.
These gaps compromise our ability to accu-
rately determine whether environmental
chemicals interact with the thyroid system
and, if they do, whether the consequence of
exposure is adverse. This is particularly
important considering that a large number
of chemicals are known to interfere with
thyroid functioning and perhaps thyroid
hormone action (28–32).
Our goal in this article is to briefly
review the data that have led us to make the
novel proposal that some environmental
chemicals can disrupt thyroid hormone sig-
naling without affecting circulating levels of
thyroid hormone, including data from our
laboratory. An important theme in this arti-
cle is that measures of thyroid function such
as blood levels of hormones and the
processes regulating these levels are not
equivalent to measures of thyroid hormone
action at the receptor, such as the regulation
of gene expression and the developmental
processes on which they act. To provide
context for this proposition, we review the
literature on thyroid hormone and brain
development and the effects of polychlori-
nated biphenyls (PCBs) on this system.
Thyroid Hormone and Brain
Development in Humans
The neonatal period of development in
humans is known to be sensitive to thyroid
hormone, especially as revealed in the disorder
known as congenital hypothyroidism (CH)
(16,18,19,21,22,33–37). CH occurs at a rate
of approximately 1 in 3,500 live births (16).
Because CH infants do not present a speciﬁc
clinical picture early, their diagnosis based
solely on clinical symptoms was delayed before
neonatal screening for thyroid hormone. In
fact, only 10% of CH infants were diagnosed
within the ﬁrst month, 35% within 3 months,
70% within the first year, and 100% only
after age 3 (38,39). The intellectual deﬁcits as
a result of this delayed diagnosis and treatment
were profound. One meta-analysis found that
the mean full-scale intelligence quotient (IQ)
of 651 CH infants was 76 (20). Moreover, the
percentage of CH infants with an IQ above 85
was 78% when the diagnosis was made within
3 months of birth, 19% when it was made
between 3 and 6 months, and 0% when diag-
nosed after 7 months of age (20,40). Studies
now reveal that the long-term consequences of
CH are subtle if the diagnosis is made early
and treatment is initiated within 14 days of
birth (36,37,41–43), which can be accom-
plished only by mandatory screening for thy-
roid function at birth. This medical proﬁle has
become the principal example illustrating the
importance of thyroid hormone for normal
brain development.
Recent studies indicate that thyroid
hormone is also important during fetal
development. Thyroid hormones are
detected in human coelomic and amniotic
ﬂuids as early as 8 weeks of gestation, before
the onset of fetal thyroid function at 10–12
weeks (44). In addition, human fetal brain
tissues express thyroid hormone receptors
(TRs), and receptor occupancy by thyroid
hormone is in the range known to produce
physiological effects as early as 9 weeks of
gestation (45,46). Finally, the mRNAs
encoding the two known TR classes exhibit
complex temporal patterns of expression dur-
ing human gestation (47), and the mRNAs
encoding these TR isoforms are expressed in
the human oocyte (48). These data indicate
that maternal thyroid hormone is delivered
to the fetus before the onset of fetal thyroid
function, and that the minimum require-
ments for thyroid hormone signaling are
present at this time.
Two kinds of pathological situations
reveal the functional consequences of deﬁcits
in thyroid hormone during fetal develop-
ment. The ﬁrst is that of cretinism, a condi-
tion usually associated with severe iodine
insufﬁciency in the diet (15). There are two
forms of cretinism based on clinical presen-
tation: neurological cretinism and myxede-
matous cretinism (15,17). Neurological
cretinism is characterized by extreme mental
retardation, deaf-mutism, impaired volun-
tary motor activity, and hypertonia (15). In
contrast, myxedematous cretinism is charac-
terized by less severe mental retardation and
all the major clinical symptoms of persistent
hypothyroidism (15). Iodide administration
to pregnant women in their first trimester
eliminates the incidence of neurological cre-
tinism. However, the initiation of iodine
supplementation by the end of the second
trimester does not prevent neurological
damage (15,49). Several detailed studies of
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world have led to the proposal that the vari-
ous symptoms of the two forms of cretinism
arise from thyroid hormone deficits occur-
ring at different developmental windows of
vulnerability (15,17,49). Therefore, thyroid
hormone appears to play an important role
in fetal brain development, perhaps before
the onset of fetal thyroid function.
The second type of pathological situation
is that of subtle, undiagnosed maternal
hypothyroxinemia. The concept and deﬁni-
tion of maternal hypothyroxinemia were
developed in a series of papers by Man et al.
(50–56). Low thyroid hormone was initially
deﬁned empirically—those pregnant women
with the lowest butanol-extractable iodine
among all pregnant women (55,57). This
work was among the first to document an
association between subclinical hypothy-
roidism in pregnant women and neurological
function of the offspring. After the develop-
ment of radioimmunoassay for thyroid hor-
mone, Pop et al. (58) found that the presence
of antibodies to thyroid peroxidase in preg-
nant women, independent of thyroid hor-
mone levels per se, is associated with
significantly lower IQ in the offspring.
Subsequent studies have shown that children
born to women with thyroxine (T4) levels in
the lowest 10th percentile of the normal range
had a higher risk of low IQ and attention
deﬁcit (25). Excellent recent reviews discuss
these studies in detail (24,57,59). Taken
together, these studies present strong evi-
dence that maternal thyroid hormone plays a
role in fetal brain development before the
onset of fetal thyroid function, and that thy-
roid hormone deficits in pregnant women
can produce irreversible neurological effects
in their offspring (18,19,22,37,60–62).
Thyroid Hormone and Brain
Development in Experimental
Animals
Considerable research using experimental
animals has provided important insight
into the mechanisms and consequences of
thyroid hormone action in brain develop-
ment. The body of this work is far too
extensive to review here but has been
reviewed at critical times during the past 50
years (4,6,11,12,18,57,63–66). Several
themes have emerged that provide a frame-
work in which to begin to understand the
role of thyroid hormone in brain develop-
ment. First, the majority of biological
actions of thyroid hormone appear to be
mediated by TRs, which are ligand-depen-
dent transcription factors (67,68). There
are two genes, encoding TRα and TRβ,
although these two receptors do not exhibit
different binding characteristics for T4 and
for triiodothyronine (T3). Second, based on
considerable work in the cerebellum, there
appear to be critical periods of thyroid hor-
mone action during development. As origi-
nally defined (69), the critical period was
that developmental stage where thyroid
hormone replacement to CH children
could improve their intellectual outcome.
This definition was also applied to experi-
mental studies to identify the developmen-
tal period during which thyroid hormone
exerts a specific action. It is now generally
accepted that there is no single critical
period of thyroid hormone action on brain
development, either in humans (15) or in
animals (70). Rather, thyroid hormone acts
on a specific development process during
the period that the process is active. For
example, thyroid hormone effects on cellu-
lar proliferation would necessarily be lim-
ited to the period of proliferation for a
speciﬁc brain area. Because cells in different
brain regions are produced at different
times (71), the critical period for thyroid
hormone action on cell proliferation would
differ for cells produced at different times.
Maternal Thyroid Hormone
and Fetal Brain Development
We recently initiated a series of studies to test
the broad hypothesis that thyroid hormone
of maternal origin can exert direct effects on
brain development before birth. Fetal thyroid
function begins in the rat at approximately
embryonic day 17.5 (E17.5) (72,73); there-
fore, thyroid hormone effects exerted before
this time would indicate a role for thyroid
hormone of maternal origin in fetal brain
development. Because thyroid hormone is
known to inﬂuence many cellular and devel-
opmental processes (11,12), the specific
genes regulated by thyroid hormone are not
possible to predict a priori. Therefore, we
used the nonbiased method of differential
display (74) to identify putative thyroid
hormone-responsive genes in the fetal cerebral
cortex. Moreover, to increase the likelihood of
identifying genes that are directly regulated by
thyroid hormone, we used a model of acute
thyroid hormone exposure (70).
We identified several putative thyroid
hormone–responsive genes in the fetal
cortex, including neuroendocrine-specific
protein A (NSP-A), Oct-1, and RC3/neuro-
granin (70,75,76). Identification of these
genes as thyroid hormone responsive in the
fetal cortex before the onset of fetal thyroid
function represents important evidence that
maternal thyroid hormone can directly
affect brain development. Interestingly, all
of these genes are selectively expressed in the
ventricular zone of the G16 cortex, where
cells undergo proliferation before commit-
ting to a speciﬁc fate (77–80). Therefore, we
tested whether thyroid hormone affects cell
proliferation in the ventricular zone using
bromodeoxyuridine (BrdU). This com-
pound is incorporated into newly synthe-
sized DNA and can be localized
immunocytochemically (81). We found that
manipulation of maternal thyroid status did
not alter the number of BrdU-labeled cells
in the ventricular zone (82); therefore, we
concluded that thyroid hormone does not
affect the number of cells being produced in
the developing cortex.
Recently, we found that thyroid hormone
enhanced contact-dependent signaling
among cells in the ventricular zone of the
E16 cerebral cortex. (83). This signaling
system is mediated by the Notch receptor.
Originally identified in Drosophila, the
Notch receptor is a membrane-bound pro-
tein whose extracellular domain can bind
to a ligand such as Delta or Jagged, pro-
teins that also are membrane bound (84).
Upon ligand binding, the Notch receptor
is cleaved by a gamma-secretase activity,
which liberates the Notch intracellular
domain to translocate to the nucleus and
regulate gene expression (85). An impor-
tant gene regulated by Notch signaling is
the basic helix-loop-helix gene HES-1
[Hairy-Enhancer of Split (86)]. Because
HES expression appears to inhibit neuro-
genesis and favor gliogenesis (87–90), we
are presently pursuing the working hypoth-
esis that thyroid hormone of maternal ori-
gin is involved in controlling the balance
in production of neurons and glia in the
ventricular zone of the early cerebral cor-
tex. This hypothesized role of thyroid hor-
mone in fate specification of neural stem
cells is similar to the role of thyroid hor-
mone in the control of oligodendrocyte
differentiation (91,92).
Taken together, our studies demonstrate
that maternal thyroid status is important to
the neurological outcome of the offspring,
and that thyroid hormone of maternal origin
can selectively affect gene expression in the
fetal cortex, perhaps by modifying Notch
signaling. It is also important to recognize
that the actions of thyroid hormone will
depend on the developmental events occur-
ring at the time under investigation. For
example, cerebellar granule cells are gener-
ated after birth in the rat, but cerebral corti-
cal neurogenesis occurs between E13 and
E17 (71). Therefore, it is predictable that
thyroid hormone does not play a signiﬁcant
role in cerebellar granule cell proliferation on
E16 or in cortical neurogenesis on postnatal
day 5 (P5). Thus, the concept of a “critical
period” of thyroid hormone action on brain
development should be restricted to speciﬁc
developmental events and not be viewed as a
single window of brain development to
which thyroid hormone action is limited.
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Considering that thyroid hormone of
maternal origin is important in fetal brain
development and neurological outcome of
the offspring, environmental factors that
affect maternal thyroid function, or thyroid
hormone action directly, may affect fetal
brain development and neurological out-
come. Although a number of environmen-
tally relevant compounds are known to
affect thyroid status (93), we focus on
PCBs in this review because their effects on
the thyroid system illustrate several impor-
tant concepts of thyroid toxicology that
may not be generally appreciated.
Polychlorinated biphenyls are a class of
industrial compounds consisting of paired
phenyl rings with various degrees of chlori-
nation (94–96). They are now ubiquitous,
persistent environmental contaminants rou-
tinely found in samples of human and ani-
mal tissues. Exposure to PCBs is associated
with cognitive and behavioral changes in
humans (97–100). The effects of PCBs on
brain development may be attributable, at
least in part, to their ability to affect the thy-
roid system (101). This hypothesis is sup-
ported in part by the overlap in neurological
deﬁcits observed in humans associated with
PCB exposure and those deficits observed
in the offspring to hypothyroxinemic
women (36,41,102,103).
PCB body burden also has been associ-
ated with measures of thyroid hormones in
humans, although these data are complex.
For example, Hagmar et al. (103) found a
signiﬁcant inverse association between serum
levels of PCB 153 and total T3 in fisher-
men’s wives from the Swedish east coast.
However, this association was not observed
in men (104). Furthermore, Sala et al. (105)
found that serum levels of both hexa-
chlorobenzene and PCBs were inversely
related to serum total T4. Persky et al. (106)
recently found that serum PCB levels were
inversely related to serum total T4 and free
T4 in women but only to total T4 in men.
Osius et al. (107) studied 7- to 10-year-old
school children in three German municipali-
ties and found a signiﬁcant positive correla-
tion between serum concentration of the
mono-ortho congener PCB 118 and serum
thyrotropin (TSH). Moreover, they found a
signiﬁcant negative correlation between sev-
eral PCB congeners and free T3. They found
no correlation between circulating levels of
PCBs and T4. In contrast, Koopman-
Esseboom et al. (108) measured dioxins and
PCBs in human cord blood and breast milk
and found that PCB exposure, estimated by
toxic equivalents, was negatively correlated
with circulating T4 in infants.
It is important to recognize that the
differences in circulating levels of thyroid
hormones associated with PCBs are still
within the normal range. Therefore, there is
no formal evidence for background exposure
to PCBs causing overt hypothyroidism.
Because different studies reveal different
associations between body burden of PCBs
and various measures of thyroid hormone
levels, it is possible that these associations are
spurious. However, it is also possible that the
environmental mixture to which different
populations are exposed can produce slightly
different effects.
All studies to date that focus on the rela-
tionship between PCBs and the thyroid use
circulating levels of thyroid hormone as the
sole indicator of an effect on the thyroid sys-
tem, or focus on mechanisms by which
PCBs affect thyroid hormone levels.
Therefore, the prevailing view is that PCBs
interfere with thyroid hormone signaling by
reducing circulating levels of thyroid hor-
mone, thereby limiting the hormone avail-
able to act on tissues (109–111). However,
the developmental effects of PCB exposure
in experimental animals are not fully consis-
tent with a mechanism attributable to
hypothyroidism. For example, PCB expo-
sure induces hearing loss in rats (109) that is
similar to that observed in hypothyroid rats
(112). Moreover, this PCB-induced hearing
loss can be at least partially restored in PCB-
treated rats by thyroid hormone replacement
(110). However, circulating levels of TSH
were not elevated by PCB exposure as it is
after exposure to the goitrogen propylth-
iouracil (109,113). Moreover, the timing of
eye opening was advanced by PCB exposure,
rather than delayed after exposure to the
goitrogen 6-n-propyl-2 thiouracil (109).
These and other observations suggest that
the combination of PCB congeners present
in the commercial Aroclor mixtures pro-
duces heterogeneous effects on the thyroid
system (101).
There are 209 PCB congeners based on
the number and placement of the chlorine
atoms in the biphenyl backbone (114). Some
investigators categorize PCB congeners
according to their dioxinlike activity (96).
PCBs with zero or one ortho chlorine, two
para chlorines, and at least two meta chlo-
rines can adopt a planar structure similar to
that of 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and can bind to and activate the
aryl hydrocarbon receptor (AhR) (96,115).
In contrast, some ortho-substituted PCBs
may adopt a non-coplanar conformation that
does not act through the AhR but can never-
theless produce neurotoxic effects (115–117).
In general, congener-specific studies
demonstrate that both coplanar and
non-coplanar PCB congeners can reduce
circulating levels of T4. However, the
mechanism(s) by which different congeners
lead to changes in circulating levels of thy-
roid hormones appears to differ. At least
three independent, but perhaps interacting,
mechanisms may account for the ability of
PCBs to reduce circulating levels of thyroid
hormone [see Brouwer et al. (111) for full
discussion]. First, PCBs have been reported
to alter the structure of the thyroid gland,
perhaps directly affecting thyroid function
(118–120). These observations, although
not extensively investigated, are consistent
with the report of Byrne et al. (121) that
PCB exposure reduces the ability of TSH to
increase serum T4 in vivo. Thus, PCBs may
directly interfere with the ability of the thy-
roid gland to respond to TSH. Second,
PCBs can alter thyroid hormone metabo-
lism. Early work demonstrated that PCB
exposure increased the rate of bile ﬂow and
increased the biliary excretion of 125I-T4
(122). Moreover, PCB exposure induces
the expression and activity of UDP-
glucuronosyltransferase (123) and increases
T4 glucuronidation (124). In addition, PCB
exposure selectively activates the glu-
curonidation of T4 but not T3 (113), sug-
gesting that this mechanism may account in
part for the failure of PCBs to alter circulat-
ing T3. Thus, PCB exposure may facilitate
T4 clearance from serum through liver
metabolism, reducing the half-life of T4 in
the blood. Finally, specific PCB congeners
can bind to thyroid hormone–binding pro-
teins in the blood and potentially can dis-
place T4 from the protein in vivo (111,125).
These three mechanisms may combine to
reduce the carrying capacity of the blood for
T4, reduce the serum half-life of T4, and
reduce the ability of the thyroid gland to
respond to TSH. Although it is not clear
which among these potential mechanisms
are most important for mediating the effects
of PCBs on circulating levels of thyroid hor-
mone, it is likely that all are important to
some extent in experimental systems.
A number of studies have focused on the
structural requirements of individual PCB
congeners required for binding to the T4-
binding protein transthyretin (125–128).
These studies demonstrate that individual
PCB congeners can displace T4 from these
proteins with high afﬁnity. In addition, sev-
eral investigators have speculated that cer-
tain PCB congeners may affect brain
development by directly interacting with
TRs (129–132), although the TRs are T3-
binding proteins that are structurally and
evolutionarily unrelated to transthyretin.
However, this concept is important to con-
sider, because many studies have demon-
strated the ability of environmental
chemicals to bind directly to estrogen and
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action with the TR is possible. In addition,
although the two TR types bind to T3 and
to T4 similarly, a number of analogs can
differentiate between the two receptors. For
example, 3,5,3′-triiodithyroacetic acid has a
much higher affinity for the TRβ1 than
does T3 (134). In addition, the compound
GC-1 is a TRβ-selective agonist (134,135).
Moreover, the therapeutic agent desethy-
lamiodarone is a noncompetitive inhibitor
of T3 binding to TRβ1 but a competitive
inhibitor of T3 binding to TRα1
(136,137). These studies demonstrate that
the two classes of TRs (TRα and TRβ) can
discriminate between ligands that may
include compounds such as PCBs.
Moreover, it is possible in principle that
individual PCB congeners could produce
allosteric effects on TR action, modifying
their ability to interact with dimerization
partners or cofactors (131). These inter-
actions are not simple to fully evaluate but
are important to address.
Because very few thyroid hormone–
responsive end points have been evaluated to
test whether PCBs act on the thyroid hor-
mone system solely by reducing circulating
levels of thyroid hormone, we tested this
hypothesis in the early postnatal rat brain.
During the ﬁrst 3 postnatal weeks in the rat
and mouse, two genes have been most exten-
sively studied for their responsiveness to thy-
roid hormone: RC3/neurogranin in the
forebrain and myelin basic protein (MBP) in
the cerebellum (138–141). The expression
of both of these genes is up-regulated by thy-
roid hormone (139,142). Interestingly,
MBP expression in the cerebellum and
RC3/neurogranin expression in the fore-
brain are affected by thyroid hormone dur-
ing a specific period from about P7 to P25
(64). Therefore, we employed RC3/neuro-
granin and MBP gene expression during this
developmental period as end points of thy-
roid hormone action to test the effects of
PCB exposure.
For this experiment, we fed pregnant rats
doses of Aroclor 1254 (A1254), from E6 to
P21, as initially reported by Goldey et al.
(109). These doses (1, 4, and 8 mg/kg)
reduced circulating levels of thyroid hor-
mones in the pups during the first 3 post-
natal weeks in a dose-dependent manner.
The highest dose, 8 mg/kg, reduced circulat-
ing T4 to undetectable levels; however,
RC3/neurogranin and MBP mRNA levels
were both significantly increased by PCB
exposure in a dose-dependent manner (143).
Importantly, this effect of A1254 on
RC3/neurogranin and MBP expression was
observed on P15 but not on P5 or P30.
Moreover, A1254 increased RC3/neuro-
granin expression only in brain areas in
which it is increased by thyroid hormone
(144). Finally, A1254 increased cellular lev-
els of RC3/neurogranin mRNA, suggesting a
transcriptional mechanism similar to that
induced by thyroid hormone (144). These
data are consistent with the interpretation
that speciﬁc PCB congeners exert a thyroid
hormonelike effect on the expression of these
genes. These data cannot be explained by the
ability of PCBs to reduce circulating levels of
thyroid hormone.
We then tested whether A1254 could
affect gene expression in the fetus, using
genes previously identified as thyroid hor-
mone responsive [(70,75,76), and reviewed
here]. We found that A1254, provided to
the dam from E6 to E16, increased
RC3/neurogranin expression in the E16 fetal
cortex (145). In addition, A1254 increased
the expression of Oct-1 mRNA in the fetal
brain but had no effect on the expression of
NSP-C (145). NSP-C is a splicing variant of
NSP-A, which we have shown is not regu-
lated by thyroid hormone in the E16 cortex
(70,76). Importantly, the same doses of
A1254 that signiﬁcantly reduced circulating
levels of thyroid hormone in neonatal ani-
mals had no effect on circulating levels of
thyroid hormones in the dams. Thus, the
ability of PCBs to affect circulating levels of
thyroid hormone is not related to their abil-
ity to affect thyroid hormone–responsive
gene expression. This observation is consis-
tent with the interpretation that PCB con-
geners responsible for reducing circulating
levels of thyroid hormone in the rat are not
the same congeners producing thyroid hor-
monelike effects on gene expression in the
developing brain.
It will be important to determine the
functional consequences of PCB effects on
thyroid hormone–responsive genes in the
fetal brain. For this reason, we have begun to
explore the effects of PCB exposure on
Notch signaling and have found that A1254
produces thyroid hormonelike effects on
HES-1 expression in the E16 brain (146).
Our working hypothesis is that PCBs
increase HES-1 expression in the fetal cor-
tex, which increases gliogenesis at the
expense of neurogenesis. Clearly, the pres-
ence of an environmental contaminant that
affects the balance of production of neurons
and glia in the absence of effects on circulat-
ing levels of thyroid hormone is an impor-
tant observation with implications for
screening programs that use circulating levels
of thyroid hormone as the sole index of
thyroid toxicology.
The parsimonious explanation for these
findings is to propose that individual PCB
congeners, or classes of congeners, can
directly activate the TR either as parent con-
geners or after metabolic activation. If true,
then individual PCB congeners should be
able to bind to the TR (or TRs) with high
afﬁnity. Presently, only one study has tested
this hypothesis formally (128), and although
the investigators found that individual
hydroxylated PCB congeners can bind to the
TRβ1 with low afﬁnity (Ki ~ 32 mM), it is
questionable that this level of binding is
physiologically meaningful. Thus, this pre-
diction remains to be fully tested.
Conclusions
Thyroid hormone is essential for brain devel-
opment both before and after birth.
Therefore, it is important to effectively eval-
uate whether environmental factors can
interfere with maternal or neonatal thyroid
function, or thyroid hormone action. We
need to improve upon our ability to identify
thyroid-disrupting environmental chemicals
for several reasons. First, we know surpris-
ingly little about the molecular and cellular
mechanisms by which thyroid hormone
affects brain development. Moreover, we
know even less about the developmental
events affected by thyroid hormone at any
one time in brain development. Therefore,
we have few clear and quantitative end
points of thyroid hormone action in brain
development that can be validated as end
points of thyroid toxicity. Toxicological
studies underlying risk assessment for thy-
roid toxicity must rely on measures of thy-
roid function such as hormone levels and
thyroid histopathology (147). Therefore,
environmental chemicals are tested for their
ability to disrupt thyroid hormone action by
measuring whether they are able to affect cir-
culating levels of thyroid hormone. The
example of PCB exposure on thyroid hor-
mone–responsive genes described here
demonstrates that thyroid hormone action
may well be disrupted without changes to
overt measures of thyroid function. Thus,
we must develop biomarkers of thyroid hor-
mone action in brain development that can
be employed in toxicological studies for risk
assessment (147).
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